N/A
N=20
Image Quality and Radiation Dose in Angiography
Arteriovenous Malformations · Aneurysm · Stenosis · Dural Arteriovenous Malformations
Bottom Line
View on ClinicalTrials.gov: NCT01381952 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2014
Primary outcome: Primary: Image Quality. For Each Included Participant 2 Images (1 AlluraXper; 1 AlluraClarity) Were Evaluated. — 9.4; 11.9; 13.1; 14.1 Scores on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology. (Radiation); Normal dose DSA with conventional X-ray technology (Radiation)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Karolinska University Hospital
- Primary completion
- Aug 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Image Quality. For Each Included Participant 2 Images (1 AlluraXper; 1 AlluraClarity) Were Evaluated. |
9.4; 11.9; 13.1; 14.1; 11.1; 12.1 | — |
| SECONDARY Radiation Dose Measurements: Dose Area Product (DAP) |
72.4 | — |
Summary
ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . The final effect on the clinical image quality is investigated in this study.
Eligibility Criteria
Inclusion Criteria
- Age 18-80
- Normal kidney function
- Neurologically intact
- Planned for diagnostic angiography or endovascular treatment
Exclusion Criteria
- Pregnancy
- Other conditions that limit the use of contrast media or ionizing radiation
Data sourced from ClinicalTrials.gov (NCT01381952). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.